Dutch pension fund dumps Mylan on worries about death penalty drug

Europeans have had a bone to pick with companies supplying death penalty drugs to U.S. prisons, with government officials restricting exports and prompting shortages. In the latest chapter of the saga, a Dutch pension fund is selling out of Mylan ($MYL) after discovering that one of its products is stocked at a U.S. prison that carries out executions. More from FiercePharma

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.